Andy Hsieh

Stock Analyst at William Blair

(0.61)
# 3,943
Out of 4,918 analysts
12
Total ratings
42.86%
Success rate
-16.24%
Average return

Stocks Rated by Andy Hsieh

Corbus Pharmaceuticals Holdings
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $9.31
Upside: -
Skye Bioscience
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $3.41
Upside: -
Altimmune
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $3.61
Upside: -
Terns Pharmaceuticals
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $5.47
Upside: -
Structure Therapeutics
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $17.61
Upside: -
BioAge Labs
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $4.12
Upside: -
Mersana Therapeutics
Feb 6, 2025
Initiates: Outperform
Price Target: n/a
Current: $6.60
Upside: -
Pyxis Oncology
Nov 21, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.10
Upside: -
Lantheus Holdings
Sep 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $70.57
Upside: -
FibroGen
Jun 26, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $6.89
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $1.61
Upside: -